Aripiprazole: A review of its pharmacology and clinical use

International Journal of Clinical Practice

Volumn 57, Issue 1, 2003, Pages 49-54

  Taylor, David M ^a  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OMEPRAZOLE; PLACEBO; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; VALPROIC ACID; WARFARIN;

ACUTE DISEASE; AKATHISIA; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERPROLACTINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; MAINTENANCE THERAPY; MANIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; RELAPSE; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; TACHYCARDIA; TARDIVE DYSKINESIA; TREMOR; VOMITING;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; HUMANS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 0037263345     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Knapp M. Costs of schizophrenia. Br J Psychiatry 1997; 171: 509-518.
2. Delay J, Deniker P. Le traitment des psychoses par une neurolyptique derivée de l'hibernotherapi: congrés des medicins aliensites et neurologistes de France 1952; 50: 497.
3. Kane J, Honigfeld G, Singer J et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
4. Taylor D, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000; 14: 409-418.
5. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf 2000; 22: 195-214.
6. National Institute of Clinical Excellence. Technology Appraisal Guidance No. 43. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London, 2002.
7. Taylor D, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000; 101: 416-432.
8. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001; 16: 63-73.
9. Taylor D. Antipsychotics and QT prolongation. Acta Psychiatr Scand 2002. In press.
10. Tauscher J, Kapur S. Choosing the right dose of antipsychotics in schizophrenia. CNS Drugs 2001; 15: 671-678.
11. Burris KD, Molski TF, Ryan E et al. Aripiprazole, is a high affinity partial agonist at human D2 dopamine receptors. Int J Neuropsychopharmacol 2000; 3(suppl 1): S129.
12. Altar CA, Inoue Y, Okazaki H et al. Aripiprazole A novel antipsychotic is a partial agonist at cultured rat pituitary cells. American College of Neuropsychopharmacology, 39th annual meeting, December 2000, San Juan, Puerto Rico.
13. 123I] iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology 2002; 162: 42-49.
14. 11C] raclopride. Neuropsychopharmacology 2002; 27: 248-259.
15. Hirose T, Uwahodo Y, Yamada S et al. Efficacy and favourable side-effect profile of aripiprazole determined in rats with apomorphine-induced stereotypy, catalepsy, and ptosis induction. Int J Neuropsychopharmacol 2000; 3(suppl 1): S131.
16. Nakai S, Hirose T, Uwahodo Y et al. Catalepsy and striato-limbic dopamine metabolism following chronic aripiprazole, risperidone and haloperidol. Int J Neuropsychopharmacol 2000; 3(suppl 1): S97.
17. IA receptor. Eur J Pharmacol 2002; 441: 137-140.
18. McQuade R, Burris KD, Jordan S et al. Aripiprazole: a dopamine-serotonin system stabiliser. Int J Neuropsychopharmacol 2002; 5(suppl 1): S176.
19. Mallikaarjun S, Salazar DE, Bramer SL. The pharmacokinetics, tolerability and safety of aripiprazole following single and multiple oral dose administration in normal volunteers. Int J Neuropsychopharmacol 2000; 3(suppl 1): S123.
20. Bristol-Myers Squibb. Data on file.
21. Citrome L, Josiassen R, Bark N et al. Pharmacokinetics and safety of aripiprazole and concomitant mood stabilizers. Int J Neuropsychopharmacol 2002; 5(suppl 1): S187.
22. Mallikaarjun S, Tammara BK, Salazar DE et al. The effects of hepatic impairment on the pharmacokinetics of aripiprazole. Clin Pharmacol Ther 2002; 71: TPII-91.
23. Blumer JL, Findling R, Kauffman R et al. Pharmacokinetics (PK), tolerability and safety of aripiprazole (AR) in children (C) and adolescents (AD) with conduct disorder. Clin Pharmacol Ther 2002; 71: MPI-3.
24. Mallikaarjun S, Ali MW, Salazar DE et al. The effects of age and gender on the pharmacokinetics of aripiprazole. Clin Pharmacol Ther 2002; 71: TPII-90.
25. Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new atypical antipsychotic: phase 2 clinical trial results. Eur Neuropsychopharmacol 1997; 7(suppl 2): S227.
26. Daniel DG, Saha AR, Ingenito G et al. Aripiprazole, a novel antipsychotic: overview of a phase 2 study result. Int J Neuropsychopharmacol 2000; 3(suppl 1): S157.
27. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-771
28. Saha AR, Carson WH, Ali MW et al. Efficacy and safety of aripiprazole and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Biol Psychiatry 2001; 2(suppl 1): 305S.
29. Cornblatt B, Kern RS, Carson WH et al. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. Int J Neuropsychopharmacol 2002; 5(suppl 1): S185.
30. Pigott TA, Saha AR, Ali MW et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia. Poster presented at American Psychiatric Association. 155th annual meeting, May 2002, Philadelphia, PA, USA.
31. Kujawa M, Saha A, Ingenito GG et al. Aripiprazole for long-term maintenance treatment of schizophrenia. Poster presented at American Psychiatric Association 155th annual meeting, May 2002, Philadelphia, PA, USA.
32. Casey DE, Saha A, Ali M et al. Switching to aripiprazole monotherapy. Poster presented at American Psychiatric Association 155th annual meeting, May 2002, Philadelphia, PA, USA.
33. Saha AR, Ali MW, Ingenito G et al. Safety and tolerability of aripiprazole at doses higher than 30 mg. Poster presented at American Psychiatric Association 155th annual meeting, May 2002, Philadelphia, PA, USA.
34. Keck PE, Saha A, Iwamoto T et al. Aripiprazole vs placebo in acute mania. Poster presented at American Psychiatric Association 155th annual meeting, May 2002, Philadelphia, PA, USA.
35. Carson W, Saha AR, Iwamoto T et al. Meta-analysis of prolactin effects with aripiprazole. Int J Neuropsychopharmacol 2002; 5(suppl 1): S186.
36. Stock E, Marder SR, Saha AR et al. Safety and tolerability meta-analysis of aripiprazole in schizophrenia. Int J Neuropsychopharmacol 2002; 5(suppl 1): S185.
37. Lieberman JA, Carson WH, Saha AR et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia. Poster presented at American Psychiatric Association 155th annual meeting, May 2002, Philadelphia, PA, USA.
38. Jody D, Saha AR, Iwamoto T et al. Meta-analysis of weight effects with aripiprazole. Poster presented at American Psychiatric Association 155th annual meeting, May 2002, Philadelphia, PA, USA.
39. Stock E, Saha A, Brunell R et al. Meta-analysis of cardiac safety with aripiprazole. Poster presented at American Psychiatric Association 155th annual meeting, May 2002, Philadelphia, PA, USA.
40. Bristol-Myers Squibb. Data on file.